PriceTargets.com logo

Puma Biotechnology - PBYI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 146.48%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.84 As of 11/20/2024 01:00 AM ET
▲ +0.1 (3.65%)

This chart shows the closing price for PBYI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Puma Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PBYI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PBYI

Analyst Price Target is $7.00
▲ +146.48% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Puma Biotechnology in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 146.48% upside from the last price of $2.84.

This chart shows the closing price for PBYI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Puma Biotechnology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
8/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
7/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
5/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00
3/1/2024HC WainwrightLower TargetBuy ➝ Buy$8.00 ➝ $7.00
2/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00
9/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00
3/6/2023HC WainwrightReiterated RatingBuy$8.00
8/5/2022HC WainwrightLower TargetBuy$12.00 ➝ $8.00
7/8/2022HC WainwrightReiterated RatingBuy$12.00
5/6/2022HC WainwrightLower Target$14.00 ➝ $12.00
9/27/2021CitigroupUpgradeNeutral ➝ Buy$11.00
8/6/2021Royal Bank of CanadaLower TargetSector Perform$13.00 ➝ $6.00
8/6/2021The Goldman Sachs GroupLower TargetSell$9.00 ➝ $8.00
5/10/2021HC WainwrightReiterated RatingBuy$15.00
8/10/2020CitigroupLower TargetNeutral$14.00 ➝ $12.00
8/7/2020Leerink PartnersLower TargetMarket Perform$14.00 ➝ $10.00
6/25/2020Bank of AmericaInitiated CoverageUnderperform$9.00
5/20/2020Cantor FitzgeraldBoost TargetNeutral$14.00 ➝ $16.00
5/15/2020Leerink PartnersReiterated RatingMarket Perform
5/10/2020Royal Bank of CanadaReiterated RatingHold$13.00
5/1/2020HC WainwrightReiterated RatingBuy$15.00
4/20/2020Royal Bank of CanadaReiterated RatingHold$13.00
2/28/2020CowenReiterated RatingHold$17.00
2/26/2020HC WainwrightReiterated RatingBuy$15.00
2/4/2020Leerink PartnersReiterated RatingMarket Perform
1/27/2020Royal Bank of CanadaReiterated RatingHold$13.00
1/3/2020GuggenheimDowngradeBuy ➝ Neutral
12/12/2019HC WainwrightReiterated RatingBuy$15.00
12/6/2019HC WainwrightInitiated CoverageBuy$15.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Puma Biotechnology logo
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $2.84
Low: $2.66
High: $2.86

50 Day Range

MA: $2.75
Low: $2.42
High: $3.30

52 Week Range

Now: $2.84
Low: $2.22
High: $7.73

Volume

270,751 shs

Average Volume

468,469 shs

Market Capitalization

$139.42 million

P/E Ratio

5.92

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Puma Biotechnology?

The following equities research analysts have issued stock ratings on Puma Biotechnology in the last twelve months: HC Wainwright, and StockNews.com.
View the latest analyst ratings for PBYI.

What is the current price target for Puma Biotechnology?

0 Wall Street analysts have set twelve-month price targets for Puma Biotechnology in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 150.9%. HC Wainwright has the highest price target set, predicting PBYI will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Puma Biotechnology in the next year.
View the latest price targets for PBYI.

What is the current consensus analyst rating for Puma Biotechnology?

Puma Biotechnology currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PBYI will outperform the market and that investors should add to their positions of Puma Biotechnology.
View the latest ratings for PBYI.

What other companies compete with Puma Biotechnology?

Other companies that are similar to Puma Biotechnology include RAPT Therapeutics, Marinus Pharmaceuticals, UroGen Pharma, Annexon and GH Research. Learn More about companies similar to Puma Biotechnology.

How do I contact Puma Biotechnology's investor relations team?

Puma Biotechnology's physical mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company's listed phone number is (424) 248-6500 and its investor relations email address is [email protected]. The official website for Puma Biotechnology is www.pumabiotechnology.com. Learn More about contacing Puma Biotechnology investor relations.